Notice2025-02763
Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production Activity; PPL Healthcare dba Piramal Pharma Solutions (Piramal); (Cholesterol Medication); Philadelphia, Pennsylvania
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 19, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 32 (Wednesday, February 19, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 32 (Wednesday, February 19, 2025)]
[Notices]
[Page 9887]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-02763]
========================================================================
Notices
Federal Register
________________________________________________________________________
This section of the FEDERAL REGISTER contains documents other than rules
or proposed rules that are applicable to the public. Notices of hearings
and investigations, committee meetings, agency decisions and rulings,
delegations of authority, filing of petitions and applications and agency
statements of organization and functions are examples of documents
appearing in this section.
========================================================================
Federal Register / Vol. 90, No. 32 / Wednesday, February 19, 2025 /
Notices
[[Page 9887]]
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-8-2025]
Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production
Activity; PPL Healthcare dba Piramal Pharma Solutions (Piramal);
(Cholesterol Medication); Philadelphia, Pennsylvania
Piramal submitted a notification of proposed production activity to
the FTZ Board (the Board) for its facility within FTZ 35. The
notification conforming to the requirements of the Board's regulations
(15 CFR 400.22) was received on February 12, 2025.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific finished product(s) described in the submitted
notification (summarized below) and subsequently authorized by the
Board. The benefits that may stem from conducting production activity
under FTZ procedures are explained in the background section of the
Board's website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed
finished products would be added to the production authority that the
Board previously approved for the operation, as reflected on the
Board's website.
The proposed finished products include: bempedoic acid tablets
(180mg) and bempedoic oral suspension (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#8ee8faf4cefafcefeaeba0e9e1f8"><span class="__cf_email__" data-cfemail="deb8aaa49eaaacbfbabbf0b9b1a8">[email protected]</span></a>. The closing period for their receipt is March 31, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Kolade Osho at
<a href="/cdn-cgi/l/email-protection#63280c0f0207064d2c100b0c2317110207064d040c15"><span class="__cf_email__" data-cfemail="cd86a2a1aca9a8e382bea5a28db9bfaca9a8e3aaa2bb">[email protected]</span></a>.
Dated: February 12, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-02763 Filed 2-18-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 19, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.